P

Pfizer

Profile managed by Bizz Id
United States 1849

Description

Biopharmaceutical company that develops and markets medicines and vaccines. Its portfolio includes monoclonal antibodies, antibody-drug conjugates, recombinant proteins and biosimilars, as well as small molecules and hospital injectables.

Products

45 products
Adalimumab

Brand: Abrilada (adalimumab-afzb).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Antihemophilic factor (recombinant)

Brand: Xyntha.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Factor VIII: see suppliers →

Bevacizumab

Brand: Zirabev (bevacizumab-bvzr). Biosimilar to Avastin.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Brentuximab vedotin

Brand: Adcetris. Antibody-drug conjugate (ADC).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Brentuximab vedotin: see suppliers →

Coagulation factor IX (recombinant)

Brand: BeneFIX.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Factor IX: see suppliers →

Dazukibart

Phase 3. PF-06823859. Anti-IFN-β; dermatomyositis, polymyositis.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dazukibart: see suppliers →

Dekavil (IL-10)

Phase 1. IL-10 biologic (Philogen trial); rheumatoid arthritis.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dekavil: see suppliers →

Disitamab vedotin

Phase 3. PF-08046051. HER2-directed ADC; metastatic urothelial cancer.

Under development

Finished product (FDF)

Verified on 2026-10-21

Disitamab vedotin: see suppliers →

Elranatamab

Brand: Elrexfio (elranatamab-bcmm). BCMA-CD3 bispecific antibody; multiple myeloma. In development: further multiple myeloma settings (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Elranatamab: see suppliers →

Enfortumab vedotin

Brand: Padcev (enfortumab vedotin-ejfv). Nectin-4-directed ADC. New FDA approval: muscle-invasive bladder cancer with Keytruda. In development: Phase 3 and Phase 2.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Enfortumab vedotin: see suppliers →

Epoetin alfa

Brand: Retacrit (epoetin alfa-epbx).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Epoetin alfa: see suppliers →

Fetrastobart vedotin

Phase 3. PF-08046054. PD-L1-directed ADC; 2L+ NSCLC.

Under development

Finished product (FDF)

Verified on 2026-10-21

Fetrastobart vedotin: see suppliers →

Filgrastim

Brand: Nivestym (filgrastim-aafi).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Filgrastim: see suppliers →

Gemtuzumab ozogamicin

Brand: Mylotarg. Antibody-drug conjugate (ADC).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Gemtuzumab ozogamicin: see suppliers →

Infliximab (ref. Inflectra)

Brand: Inflectra (infliximab-dyyb).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Infliximab: see suppliers →

Infliximab (ref. Ixifi)

Brand: Ixifi (infliximab-qbtx), for intravenous use.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Infliximab: see suppliers →

Inotuzumab ozogamicin

Brand: Besponsa. Antibody-drug conjugate (ADC).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Inotuzumab ozogamicin: see suppliers →

Marstacimab

Brand: Hympavzi. Hemophilia A or B with inhibitors (expanded indication).

Aprobado FDA; Aprobado Comisión Europea

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Marstacimab: see suppliers →

Ompekimig

Phase 2. Anti-IL-4/IL-13/IL-33; atopic dermatitis.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ompekimig: see suppliers →

Pegfilgrastim

Brand: Nyvepria (pegfilgrastim-apgf).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pegfilgrastim: see suppliers →

Pegvisomant

Brand: Somavert.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pegvisomant: see suppliers →

PF-06835375 (anti-CXCR5)

Phase 2. Anti-CXCR5; immune thrombocytopenic purpura (Phase 2), lupus (Phase 1).

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-06940434 (integrin αvβ8 antagonist)

Phase 1. Biologic integrin αvβ8 antagonist; advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-07261271 (anti-p40/TL1A)

Phase 2. p40/TL1A bispecific; ulcerative colitis (Pfizer-Roche collaboration).

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-07868489 (anti-BMP9)

Phase 2. Anti-BMP9; pulmonary arterial hypertension.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046031 (ADC anti-CD228)

Phase 1. CD228-directed ADC; advanced melanoma and other solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046032 (ADC anti-CD25)

Phase 1. CD25-directed ADC; advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046033 (ADC anti-GPNMB)

Phase 1. Glycoprotein-NMB-directed ADC; advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046040 (anti-CD70)

Phase 1. Non-fucosylated CD70-directed antibody; MDS and AML.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046044 (ADC anti-CD30)

Phase 1. CD30-directed antibody-TOPO1 drug conjugate; advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046050 (ADC anti-CEACAM5)

Phase 1. CEACAM5-directed ADC; advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08046876 (ADC anti-integrin β6)

Phase 1. Integrin beta-6-directed ADC (B6C); advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08052666 (ADC anti-mesothelin)

Phase 1. Mesothelin-targeted ADC; advanced solid tumors.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08052667 (ADC anti-integrin β6)

Phase 1. Integrin beta-6-directed ADC (B6N); non-muscle-invasive bladder cancer.

Under development

Finished product (FDF)

Verified on 2026-10-21

PF-08634404 (anti-PD-1/VEGF)

Phase 3. PD-1xVEGF bispecific antibody; metastatic colorectal cancer, NSCLC; other indications in Phase 2 and Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ponsegromab

Phase 2. PF-06946860. Anti-GDF15 monoclonal antibody; cancer cachexia.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ponsegromab: see suppliers →

Rituximab

Brand: Ruxience (rituximab-pvvr). Biosimilar to Rituxan.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rituximab: see suppliers →

Sasanlimab

Phase 3. PF-06801591. Anti-PD-1 (with BCG); high-risk non-muscle-invasive bladder cancer.

Under development

Finished product (FDF)

Verified on 2026-10-21

Sasanlimab: see suppliers →

Sigvotatug vedotin

Phase 3. PF-08046047. Integrin beta-6-directed ADC; metastatic NSCLC.

Under development

Finished product (FDF)

Verified on 2026-10-21

Sigvotatug vedotin: see suppliers →

Somatrogon

Brand: Ngenla (somatrogon-ghla).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Somatrogon: see suppliers →

Somatropin

Brand: Genotropin (somatropin [rDNA origin]).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Somatropin: see suppliers →

Taliglucerase alfa

Brand: Elelyso.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Taliglucerase alfa: see suppliers →

Tilrekimig

Phase 2. PF-07275315. Anti-IL-4/IL-13/TSLP; atopic dermatitis, asthma, COPD.

Under development

Finished product (FDF)

Verified on 2026-10-21

Tilrekimig: see suppliers →

Tisotumab vedotin

Brand: Tivdak (tisotumab vedotin-tftv). Tissue factor-directed ADC. In development: solid tumors (Phase 2).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Tisotumab vedotin: see suppliers →

Trastuzumab

Brand: Trazimera (trastuzumab-qyyp). Biosimilar to Herceptin.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free